menu
    • menu
    [{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Urofollitropin","moa":"Follicle stimulating hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IBSA Institut Biochimique \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"IBSA Institut Biochimique \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Urofollitropin","moa":"Follicle stimulating hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Urofollitropin","moa":"Follicle stimulating hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Menotropins","moa":"Follicle-stimulating hormone receptor; Lutropin-choriogonadotropic hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Menotropins","moa":"Follicle-stimulating hormone receptor; Lutropin-choriogonadotropic hormone receptor||Luteinizing hormone\/Choriogonadotropin receptor | Follicle stimulating hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Ferring Arzneimittel GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Menotropins","moa":"Luteinizing hormone\/Choriogonadotropin receptor | Follicle stimulating hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ferring Pharmaceuticals \/ Ferring Arzneimittel GmbH","highestDevelopmentStatusID":"11","companyTruncated":"Ferring Pharmaceuticals \/ Ferring Arzneimittel GmbH"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ferring Pharmaceuticals

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Ferring Pharmaceuticals

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Follitropin Delta

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ferring Announces Abstract of the First Prospective, Multi-National, Real-world Study of Rekovelle® (follitro...

                            Details : Rekovelle (follitropin delta) is a follicle-stimulating hormone made from recombinant human DNA that is used to promote follicular development in females with ovarian failure, reproduction and fertility.

                            Product Name : Rekovelle

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            March 14, 2023

                            Lead Product(s) : Follitropin Delta

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ferring Pharmaceuticals

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Ferring Pharmaceuticals

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Menotropins

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ferring Pharmaceuticals Announces New Clinical Data Published on Menopur® in a Predicted High Responder Popul...

                            Details : MEGASET-HR (high responder) study met its primary non-inferiority endpoint, with Menopur-treated patients experiencing a 35.5% ongoing pregnancy rate (OPR) per cycle start after a fresh transfer, compared to 30.7% for rFSH-treated patients

                            Product Name : Menopur

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            May 14, 2020

                            Lead Product(s) : Menotropins

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ferring Pharmaceuticals

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Ferring Pharmaceuticals

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Menotropin

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MENOPUR® in a Gonadotropin-Releasing Hormone (GnRH) Antagonist Cycle With Single-Blastocyst Transfer in a H...

                            Details : Menopur (Menotropin) is a Hormone drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Infertility.

                            Product Name : Menopur

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            September 18, 2015

                            Lead Product(s) : Menotropin

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            IBSA Institut Biochimique

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            IBSA Institut Biochimique

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Urofollitropin

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST)

                            Details : Urofollitrophin is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Infertility.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 25, 2013

                            Lead Product(s) : Urofollitropin

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ferring Pharmaceuticals

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Ferring Pharmaceuticals

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Urofollitropin

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Menopur Mixed Protocol

                            Details : Bravelle is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Infertility.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 16, 2011

                            Lead Product(s) : Urofollitropin

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ferring Pharmaceuticals

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Ferring Pharmaceuticals

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Menotropins

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase IV

                            Sponsor : Ferring Arzneimittel GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Progesterone Serum Levels in Subfertile Female Patients Undergoing in Vitro Fertilisation (IVF)

                            Details : Menogon HP (Menotrophin) is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Infertility.

                            Product Name : Menogon HP

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 21, 2010

                            Lead Product(s) : Menotropins

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase IV

                            Sponsor : Ferring Arzneimittel GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ferring Pharmaceuticals

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Ferring Pharmaceuticals

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tranexamic Acid

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lysteda Pediatric Research Equity Act (PREA) Pharmacokinetic Study in Adolescent Females With Heavy Menstrual ...

                            Details : Tranexamic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Menorrhagia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 27, 2010

                            Lead Product(s) : Tranexamic Acid

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth